Cardiovascular Disease
1,022
40
70
730
Key Insights
Highlights
Success Rate
93% trial completion (above average)
Published Results
160 trials with published results (16%)
Research Maturity
730 completed trials (71% of total)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 40/100
5.5%
56 terminated out of 1022 trials
92.9%
+6.4% vs benchmark
16%
168 trials in Phase 3/4
22%
160 of 730 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 730 completed trials
Clinical Trials (1022)
Developing the Family Map: Looking at Communal Coping
The Psoriasis, Atherosclerosis, and Cardiometabolic Disease Initiative (PACI)
Gulf Long-Term Follow-Up Study
Technical Development of Cardiovascular Magnetic Resonance Imaging
Recombinant Herpes Zoster Vaccine for Prevention of Cardiovascular Events and Dementia
Heart Health Study in Washington D.C. to Develop a Community-Based Behavioral Weight Loss Intervention
OCEAN(a)-PreEvent - Olpasiran Trials of Cardiovascular Events And LipoproteiN(a) Reduction to Prevent First Major Cardiovascular Events
Williams Syndrome (WS) and Supravalvar Aortic Stenosis (SVAS) DNA and Tissue Bank
Genetics of Obesity, Diabetes, and Heart Disease in African Diaspora Populations
Healthy Aging in Neighborhoods of Diversity Across the Life Span (HANDLS)
Risk Communication Within Mexican-American Families
Awareness of Risk Factors and Perception of Cardiovascular Risk in Secondary Prevention Among Women and Men
Impact of Elastin Mediated Vascular Stiffness on End Organs
Identification of CETP as a Marker of Atherosclerosis
Human Biospecimen Procurement Protocol: Biorepository to Support Translational Research to Identify Disease Mechanism(s)
Clinical and Molecular Characteristics of Primary Aldosteronism in Blacks
Links Between Inflammation and Cardiometabolic Diseases
A Phase III Study of AZD0780 on Major Adverse CV Events in Patients With a History of ASCVD Events or at High Risk for a First Event
Olpasiran Trials of Cardiovascular Events and Lipoprotein(a) Reduction - Coronary Computed Tomography Angiography Trial
A Novel Digital Tool Physicians Can Use to Prescribe Exercise to Patients With Cardiovascular Disease Risk Factors